Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Cash from Investing Activities (2016 - 2022)

Aptevo Therapeutics' Cash from Investing Activities history spans 8 years, with the latest figure at -$4000.0 for Q3 2022.

  • For Q3 2022, Cash from Investing Activities rose 69.23% year-over-year to -$4000.0; the TTM value through Dec 2022 reached -$135000.0, up 81.07%, while the annual FY2022 figure was -$29000.0, 95.93% up from the prior year.
  • Cash from Investing Activities for Q3 2022 was -$4000.0 at Aptevo Therapeutics, up from -$118000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $63.8 million in Q3 2018 and bottomed at -$391000.0 in Q2 2021.
  • The 5-year median for Cash from Investing Activities is -$8500.0 (2021), against an average of $12.9 million.
  • The largest annual shift saw Cash from Investing Activities soared 18479.08% in 2020 before it tumbled 100.68% in 2021.
  • A 5-year view of Cash from Investing Activities shows it stood at $63.8 million in 2018, then tumbled by 93.33% to $4.2 million in 2019, then plummeted by 102.07% to -$88000.0 in 2020, then crashed by 34.09% to -$118000.0 in 2021, then surged by 96.61% to -$4000.0 in 2022.
  • Per Business Quant, the three most recent readings for APVO's Cash from Investing Activities are -$4000.0 (Q3 2022), -$118000.0 (Q4 2021), and -$13000.0 (Q3 2021).